Page last updated: 2024-11-06

fepradinol

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Cross-References

ID SourceID
PubMed CID68819
CHEMBL ID2106269
CHEBI ID134878
SCHEMBL ID151235
MeSH IDM0210314

Synonyms (31)

Synonym
brn 2094927
g 131
alpha-(((1,1-dimethyl-2-hydroxyethyl)amino)methyl)benzyl alcohol
benzenemethanol, alpha-(((1,1-dimethyl-2-hydroxyethyl)amino)methyl)-
fepradinol
CHEBI:134878
2-[(2-hydroxy-2-phenylethyl)amino]-2-methylpropan-1-ol
63075-47-8
fepradinol (inn)
D07954
FT-0668517
36981-91-6
860mhi4wba ,
unii-860mhi4wba
CHEMBL2106269
fepradinol [inn]
fepradinolum [inn-latin]
(+-)-alpha-(((2-hydroxy-1,1-dimethylethyl)amino)methyl)benzyl alcohol
fepradinolum
AKOS008966988
1-phenyl-4,4-dimethyl-3-azapentane-1,5-diol
SCHEMBL151235
fepradinol [mart.]
(+/-)-.alpha.-(((2-hydroxy-1,1-dimethylethyl)amino)methyl)benzyl alcohol usan synonym
fepradinol [who-dd]
fepradinol [mi]
benzenemethanol, .alpha.-(((2-hydroxy-1,1-dimethylethyl)amino)methyl)-
dalgen;el-508
Q27269683
2-((2-hydroxy-2-phenylethyl)amino)-2-methylpropan-1-ol
DTXSID60866967

Research Excerpts

Overview

Fepradinol is an effective non-steroidal anti-inflammatory agent.

ExcerptReferenceRelevance
"Fepradinol is an effective non-steroidal anti-inflammatory agent. "( Effect of fepradinol on rat hind paw oedema induced by several inflammatory agents.
Conde, JR; Martorell, J; Masso, JM; Villar, AM, 1993
)
2.13

Dosage Studied

ExcerptRelevanceReference
" Oral dosing of fepradinol and cyproheptadine suppressed zymosan-induced paw edema in rats."( Mechanism of anti-inflammatory action of fepradinol.
Conde, JR; Martorell, J; Massó, JM; Villar, AM, 1994
)
0.9
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
aralkylamineAn alkylamine in which the alkyl group is substituted by an aromatic group.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (14)

TimeframeStudies, This Drug (%)All Drugs %
pre-19901 (7.14)18.7374
1990's11 (78.57)18.2507
2000's2 (14.29)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 25.95

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index25.95 (24.57)
Research Supply Index2.77 (2.92)
Research Growth Index5.39 (4.65)
Search Engine Demand Index26.67 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (25.95)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials1 (7.14%)5.53%
Reviews1 (7.14%)6.00%
Case Studies8 (57.14%)4.05%
Observational0 (0.00%)0.25%
Other4 (28.57%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]